Dyne Therapeutics Names Vikram Karnani To Its Board To Enhance Governance And Leadership

Dyne Therapeutics, Inc., a clinical-stage company focused on improving function for people living with genetically driven neuromuscular diseases, announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare diseases and the biopharmaceutical sector, currently serving as the chief executive officer of Collegium Pharmaceutical. He previously spent nearly a decade leading multiple business lines and functions at Horizon Therapeutics, gaining significant experience in driving growth and commercialization in rare disease markets.

Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture, welcomed Mr. Karnani to the Board, noting that his experience as a CEO and commercial leader at rapidly growing biotechnology companies will provide valuable insight as Dyne moves toward commercialization. Rhodes highlighted that Mr. Karnani’s expertise in product launches, business growth, and value creation will support Dyne’s efforts to generate revenue and expand its pipeline. John Cox, president and CEO of Dyne, added that Mr. Karnani’s track record in managing commercial and medical organizations will provide an important perspective as Dyne prepares for its first potential product launch in Q1 2027 and seeks to build a company with multiple opportunities to transform care for neuromuscular diseases.

Mr. Karnani expressed his enthusiasm for joining the Board, emphasizing his focus on translating innovation into successful businesses that improve patient lives. He cited Dyne’s clinically validated drug delivery platform and progress toward commercialization as key factors that underscore the company’s potential to deliver meaningful functional improvements for people with neuromuscular diseases.

Mr. Karnani has served as president and CEO of Collegium Pharmaceutical since November 2024, leading a diversified biopharmaceutical company with a strong portfolio in responsible pain management and a growing neuropsychiatry business. Before joining Collegium, he was executive vice president and president of global commercial operations and medical affairs (rare disease) at Amgen, where he oversaw the integration and growth of the company’s $4 billion rare disease business following the $28 billion acquisition of Horizon Therapeutics. 

During his nearly ten years at Horizon, Mr. Karnani held several senior executive positions, including president of global commercial operations and chief commercial officer, helping transform the company from $500 million in revenue to a rare disease leader generating over $3 billion in revenue through strategic planning, M&A, and commercialization. Earlier in his career, he held leadership roles in strategy and business development at Fresenius Kabi, as well as vice president of therapeutics and cell therapy.

Mr. Karnani holds a bachelor’s degree in electrical engineering from the University of Mumbai, a master’s degree in electrical engineering from Case Western Reserve University, and an MBA from Northwestern University’s Kellogg School of Management. His appointment strengthens Dyne’s Board as the company advances toward commercialization and prepares for its upcoming product launch.